Patent · US Active

High affinity human antibodies to human cytomegalovirus (CMV) gB protein

US10030069B2 · kind B2 · utility

0Cited by

3References

12Claims

0Family size

Assignee

Trellis Bioscience, Inc. · US

Inventors

Lawrence M. Kauvar · San Francisco, US
Stote Ellsworth · Palo Alto, US
William Usinger · Lafayette, US
Krista McCutcheon · Burlingame, US
Ying-Ping Jiang · Scotch Plains, US
Fen Zhang · San Francisco, US
Bo Chen · Jinan, CN
Gizette Sperinde · El Granada, US
Minha Park · Brisbane, US
Orit Foord · Foster City, US

Key dates

Filing date	Mar 20, 2017
Grant date	Jul 24, 2018
Priority date	—
Expiry date	Mar 20, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.